Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study.
BACKGROUND
Although cure rates in pediatric acute lymphoblastic leukemia (ALL) are quite high with combined chemotherapy regimens, complete response (CR) and long-term survival rates in adults are 80-90 and 30-40%, respectively. Currently, combined chemotherapy regimens, such as Hyper-CVAD and PETHEMA, are used in patients with adult ALL. However, there has been no study comparing the results of Hyper-CVAD and PETHEMA ALL-93.


METHODS
In this retrospective single-center study, we evaluated the results of Hyper-CVAD and PETHEMA ALL-93 in 51 ALL patients treated between September 2008 and March 2017 at the Department of Hematology, Faculty of Medicine, Karadeniz Technical University.


RESULTS
Thirty-eight patients were treated with Hyper-CVAD and 13 with PETHEMA ALL-93. CR was obtained in 90 and 100% of patients, respectively. Survival estimates were comparable between Hyper-CVAD and PE-THEMA ALL-93, with a median overall survival (OS) and a median disease-free survival (DFS) of 17.5 and 12.1 months, respectively, for Hyper-CVAD and of 18.6 and 12.9 months, respectively, for PETHEMA ALL-93. The 2-year OS rates for Hyper-CVAD and PETHEMA ALL-93 were 30 and 40%, respectively, and the 2-year DFS rates were 28 and 44%, respectively. PETHEMA ALL-93 resulted in more hepatotoxicity, hypofibrinogenemia, aspergillus infection, and skin rash than Hyper-CVAD.


CONCLUSIONS
Although Hyper-CVAD and PE-THEMA ALL-93 showed similar effects, Hyper-CVAD was tolerated better. Age and comorbidities should be taken into account before a chemotherapy regimen is determined for patients with ALL.
['Erkut|Nergiz|N|', 'Akidan|Osman|O|', 'Selim Batur|Derya|D|', 'Karabacak|Volkan|V|', 'Sonmez|Mehmet|M|']
D000293:Adolescent D000328:Adult D000971:Antineoplastic Combined Chemotherapy Protocols D001215:Asparaginase D001424:Bacterial Infections D003520:Cyclophosphamide D003907:Dexamethasone D018572:Disease-Free Survival D004317:Doxorubicin D005260:Female D005334:Fever D006801:Humans D008297:Male D015122:Mercaptopurine D008727:Methotrexate D008875:Middle Aged D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma D011241:Prednisone D012189:Retrospective Studies D015996:Survival Rate D016896:Treatment Outcome D014750:Vincristine D055815:Young Adult
Hyper-CVAD PETHEMA ALL-93 Acute lymphoblastic leukemia Survival Side effects